FDA Hanging Onto Lead in Cancer Drug Approvals, New Study Finds

Drug Industry Daily
A A
The FDA continues to approve cancer drugs more quickly than the European Medicines Agency (EMA), clearing them in about half of the time regardless of the drugs’ designation, according to a recent study.

To View This Article:

Login

Subscribe To Drug Industry Daily